Our group is especially interested in neutrophil extracellular traps, or “NETs.” If you have ever seen DNA prepared from bananas at the science museum, you know how sticky it is, and that is what neutrophils have learned to exploit. Imagine neutrophils ejecting their DNA guts as sticky spider webs coated with all sorts of molecular weapons. While NETs are perfect for capturing and killing microscopic invaders, they also turn out to be quite toxic to blood vessels when produced in excess, as happens in thrombotic and inflammatory diseases. Our group's overarching hypothesis is that by blocking NETs, we can protect blood vessels, organs, and patients.
- Clinical and translational research of antiphospholipid syndrome (APS)
- Crosstalk between the immune system and thrombosis (i.e., thrombo-inflammation)
- Role of neutrophils and neutrophil extracellular traps (NETs) in lupus and APS
- Extracellular purines as regulators of inflammation
- Endoplasmic reticulum stress responses of neutrophils
- Role of neutrophils and NETs in diabetic cardiovascular disease
Our approach to treatment recognizes that antiphospholipid syndrome is different in every person. Along with specialists in hematology, obstetrics, neurology, nephrology and more, our rheumatologists work with each patient to develop a personalized treatment approach to pursue the very best possible long-term outcome.
Make a Gift
Making a gift to the APS Gift Fund (Knight Lab) will support cutting-edge research in the U-M Division of Rheumatology, with the goal of developing better treatments, and ultimately a cure, for antiphospholipid syndrome.